Doctor of Philosophy in Pharmaceutical Sciences (PhD)
Identification of polysialylated proteins in breast cancer and correlation with patient prognosis
If you are passionate about health sciences research that makes a difference in people's lives, you're in good hands. We offer award-wining graduate programs led by world-class researchers. You'll have access to top-tier facilities and be working alongside the best and brightest in the field, conducting research that addresses real life problems. Our paradigm-changing approach is collaborative, innovative, and results-driven.
We're tackling diseases like asthma / chronic obstructive pulmonary disease, diabetes, cancer, heart disease, and arthritis. We're developing better ways to deliver drugs and prevent adverse drug reactions. And we're conducting clinical and economic research in pharmaceutical outcomes.
Our reputation as a top research centre attracts some of the brightest and most productive minds in the field. Our faculty includes Canada Research Chairs, Michael Smith Foundation for Health Research Scholars and Senior Scholars, and Distinguished University Scholars.
We are innovators in pharmacy education, research and practice, with the goal of supporting the optimization of drug therapy in the pursuit of improved patient outcomes.
adMare BioInnovations is located in our building. It is an independent, non-profit organization with a focus on bridging the gap between academic discoveries in the health sciences and the development of new medicines to treat human disease. The Faculty partners with adMare BioInnovations to provide unique research and mentoring opportunities for MSc and PhD students.
We are also home to several sophisticated research centres that specialize in the areas of human genome and exome sequencing, and health outcomes research.
Opened in 2012, the Pharmaceutical Sciences Building at UBC is a state-of-the-art learning and research facility. The building houses modern, modular labs designed specifically for the type of research intended for the space. Our classroom facilities are fitted with advanced technology to facilitate new modes of learning.
Measuring 246,000 square feet, it's an eye-catching addition to our campus, and has drawn attention and admiration from around the world—including 15 awards of excellence.
As a leading research faculty, we conduct ground-breaking research in the pharmaceutical sciences – all with the goal of addressing the pressing health needs of society and improving lives. Our research activities centre around four areas of focus.
This theme covers our activities in epidemiological analysis, health outcomes and health economics research seeking solutions for the predictive enhancement of intervention strategies for practical and preventive healthcare. The impact of this work is used to shape policy to optimize the allocation of health care resources as well as defining the efficacy of healthcare interventions and strategy.
This highly interdisciplinary theme embodies research directed at the interactions of therapeutic agents with human cells, and covers fundamental questions of the mechanisms of the drug action through to the behaviour of drugs in human systems. These studies are used to inform and optimize the development and delivery of drug intervention regimes for clinical practice and the pharmaceutical industry.
This theme applies our expertise in the chemical biology of the fabrication and handling of nanoscopic materials to drug discovery and delivery. Sensing and screening technologies are also an important focus.
Our research in this theme addresses the issue of scholarship in pharmacy and the pharmaceutical sciences with a view to augment our educational research capacity and enhance the methodologies of teaching practice, student learning and curriculum decision-making.
|Cairns, Brian||Neurosciences, biological and chemical aspects; Neurosciences, medical and physiological and health aspects; Pharmacology and pharmaceutical sciences (except clinical aspects); electrophysiology; headache; Neuropharmacology; Oro-Facial Pain; pain; pain mechanisms; peripheral analgesics; sex-related differences; temporomandibular disorders|
|Chang, Thomas||Pharmacology and pharmaceutical sciences (except clinical aspects)|
|Collier, Abby||Drugs in children, Drugs in pregnancy, Developmental pharmacology, Drug metabolism, Pharmacokinetics, Drug metabolism and pharmacokinetics, primarily of the phase II (conjugation) enzymes, focused on pregnancy and pediatrics|
|Conklin, Annalijn||Public health nutrition policy; Other basic medicine and life sciences; Chronic Diseases in Elderly; Community Health / Public Health; disease management evaluation; food and nutrition policy; Gender Epidemiology; gender and health equity; Health Policies; healthcare quality improvement; healthy ageing; Indigenous health; Obesity; obesity & CVD risk factors; Professional Practices; Social Determinants of Dietary and Metabolic Disorders; social nutritional epidemiology; ethics of research and public health|
|Coughtrie, Michael||Drug metabolizing enzymes|
|Cragg, Jacquelyn||Epidemiology (except nutritional and veterinary epidemiology); data science; open science; Causal inference; Drug Effectiveness; Drug Safety; Epidemiology; neuro-epidemiology; Neurological diseases; Spinal cord injury; Amyotrophic Lateral Sclerosis (ALS); multiple sclerosis; Parkinson’s disease|
|De Vera, Mary||examining how eHealth technologies can support new and existing models of care to improve care delivery and patient outcomes; exploring patients' perspectives and experiences with medication taking and adherence; and evaluating the use and impacts of medications among pregnant women, particularly with inflammatory conditions.|
|Finbloom, Joel||Drug discovery, design and delivery; Biologically active molecules; Nanochemistry; Antimicrobial resistance; Nanomedicine; nanomedicine; Chemical Biology; drug delivery; Pharmaceutical Sciences; Infectious disease; Bacterial Biofilms; Microbiome; Probiotics; Antibiotic resistance|
|Frankel, Adam||Other basic medicine and life sciences; Enzymes (including kinetics and mechanisms, and biocatalyst); Biological and Biochemical Mechanisms; Bioactive Molecules; Organic Molecules and Biomolecules; Proteins; arginine methylation; post-translational modifications; Chemical Biology; drug discovery; Target Engagement; Protein Biochemistry; yeast; Amino acids|
|Giaever, Guri||Model organisms, human therapeutics, high-throughput cell biology, drug synergy, technologies for understanding relationship between chromatic structure and transcriptional regulation|
|Hafeli, Urs||Pharmacology and pharmaceutical sciences, n.e.c.|
|Harrison, Mark||measurement and valuation of health, health technology and policy assessment, and preferences for healthcare interventions; evaluation/re-evaluation of the type of health care that is provided, the point in the treatment pathway, and the way in which it is delivered|
|Jarvis-Selinger, Sandra||Education, human learning, development, and instruction, education innovation, konwledge translation, teaching excellence, curriculum design, technology|
|Johnson, Kate||Health Outcomes|
|Kumar, Ujendra||Somatostatin hormone, molecular pharmacology, Somatostatin, , Hormones, somatostatin, locomotor and cognitive function, neurodegenerative diseases, drugs|
|Lalji, Fawziah||Pharmacology and pharmaceutical sciences (except clinical aspects); Pharmacoepidemiology; Infectious diseases; Vaccination; Antibiotics and Resistance; Tuberculosis|
|Lau, Tim||Clinical pharmacy and pharmacy practice; Infectious diseases; Antimicrobial Stewardship; systematic reviews; Clinical Pharmacokinetics; Clinical Pharmacy|
|Li, Shyh-Dar||Drug discovery, design and delivery; Nano-technology; biopharmaceutics; drug delivery; nanomedicine; pharmaceutics; Gene delivery and therapy|
|Loewen, Peter||Cardiology and circulatory sciences (including cardiovascular disease); Clinical pharmacy and pharmacy practice; Knowledge translation and implementation science in health; atrial fibrillation; Pharmacoepidemiology; Thrombosis and Embolism; adherence to medication; Cardiovascular diseases; Arrhythmia; Heart Failure; stroke; Health Care Technologies; Professional Practices; Hematology; decision making; clinical prediction rules; healthcare communication technologies; hospital pharmacy practice; knowledge translation of evidence to patient care; patient complexiometry; patient decision aids; patient education; pharmacy practice; prediction of stroke and bleeding in atrial fibrillation patients; quality of care, quality drug therapy; Shared decision-making; stroke prevention therapy; use of mobile technology for clinical decision-making|
|Lynd, Larry||health economics, orphan drugs, pharmaceutical policy, respiratory medicine, epidemiology, pharmacoepidemiology, rare diseases|
|Maharaj, Anil||Pharmacology and pharmaceutical sciences, n.e.c.; Pharmacometrics; Pharmacokinetics/Pharmacodynamics; Obstetric and Pediatric Pharmacology|
|McCormack, James||Knowledge translation and evidence-based practice|
|Nislow, Corey||genomics and develops biotechnology tools to address both fundamental and applied biological questions; Parallel genome-wide chemical genomic screens; High throughput cell-based screens; Next Generation Sequencing|
|Page, Brent||Pharmacology and pharmaceutical sciences (except clinical aspects); Cell Signaling and Cancer; Cancer; Cell signaling; Chemical Biology; Drug development; Drug Discovery, Design and Delivery; Medicinal Chemistry; Target Engagement|
|Rafizadeh, Reza||Other clinical medicine; Psychotic disorders, Substance Use Disorders, Clinical Research|
This is an incomplete sample of recent publications in chronological order by UBC faculty members with a primary appointment in the Faculty of Pharmaceutical Sciences.
|2022||Dr. Javed has developed breast cancer models to target primary and metastatic tumors at distant sites. She also explored the role of finger like projections-invadopodia in helping tumor cells movement through the lymphatic system. The findings from these studies will be helpful in providing an in-depth insight into targeting tumor metastasis.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2022||Dr. Khatri examined the health and economic impact of introduction of 13-pneumococcal conjugate vaccine in infant immunization program in British Columbia, Canada. This research illuminates the value of PCV13 vaccine in preventing pneumococcal disease.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2022||Dr. Price investigated the processes of inflammation, antioxidant defense, and steroidogenesis within the placenta. These studies assist us in understanding the higher rates of pregnancy complications associated with assisted reproduction technologies.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2022||Dr. Al Fayez worked on improving the effectiveness of currently available liver treatments. Her research focused on developing novel lipid-based nanoparticles for hepatocytes targeting. Dr. ALFayez believes these nanoparticles can be used as a platform to enhance the treatment of many terminal liver diseases including chronic hepatitis B infection.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2022||Dr. Nguyen developed a method to make chemical modifications to drugs that enable formation into nanoparticles for improved drug delivery and efficacy. This research will benefit a spectrum of drugs and identify new formulations that will offer safer and effective therapies for patients battling diseases like cancer and rheumatoid arthritis.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2022||Dr. Benbow developed a pre-clinical model of migraine headache using monosodium glutamate (MSG). He subsequently applied his model to identify and validate a novel drug target that may be leveraged to treat and prevent migraines in people.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2021||Dr. Salmasi measured medication taking in atrial fibrillation patients in BC. She revealed that patients exhibit distinct patterns of medication taking over time. Study findings can inform the design of interventions to improve medication taking, and ultimately avoid preventable strokes and deaths in patients with atrial fibrillation.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2021||Dr. Nosrati developed a novel drug delivery system that targets and treats rheumatoid arthritis. Her work resulted in concentrating toxic drugs in inflamed joints more effectively with less side effects, reducing inflammation more strongly and for longer periods of time. Patients with moderate to severe rheumatoid arthritis will benefit from her findings.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2021||Dr. Brown examined how protein arginine methyltransferases interact with their binding partners and identified a process by which these enzymes contribute to stress in yeast cells. Since yeast and human cells are highly similar, these results provide new knowledge of the importance and impact of this family of enzymes on biological pathways.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2021||Dr. Yang studied a special four-stranded nucleic acid structure, called the G-quadruplex, through developing new tools and methods. His collection of works provide evidence for the biological relevance and existence of these structures in living human cells.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|